## Paul F Siami

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6183632/publications.pdf

Version: 2024-02-01

516710 677142 1,726 21 16 22 h-index citations g-index papers 22 22 22 1147 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study. European Urology, 2010, 57, 123-131.	1.9	619
2	The Effects of Dutasteride, Tamsulosin and Combination Therapy on Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia and Prostatic Enlargement: 2-Year Results From the CombAT Study. Journal of Urology, 2008, 179, 616-621.	0.4	268
3	Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. Urology, 2000, 56, 130-135.	1.0	99
4	Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4â€year results from the randomized, doubleâ€blind Combination of Avodart and Tamsulosin (CombAT) trial. BJU International, 2011, 107, 946-954.	2.5	92
5	The Influence of Baseline Parameters on Changes in International Prostate Symptom Score with Dutasteride, Tamsulosin, and Combination Therapy among Men with Symptomatic Benign Prostatic Hyperplasia and an Enlarged Prostate: 2-Year Data from the CombAT Study. European Urology, 2009, 55, 461-471.	1.9	89
6	Randomized, Double-blind, Placebo-controlled Trial of Flexible-dose Fesoterodine in Subjects With Overactive Bladder. Urology, 2010, 75, 62-68.	1.0	86
7	Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart® and) Tj ETQq1 1 0.7843	3 1:48rgBT /	O <b>⊽e</b> rlock 10
8	Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. BJU International, 2005, 96, 572-577.	2.5	65
9	Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU International, 2006, 98, 1025-1032.	2.5	56
10	A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: The speed of onset of therapeutic assessment trial (STAT). Clinical Therapeutics, 2002, 24, 616-628.	2.5	51
11	Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: Results of a 12-week, multicenter, open-label, flexible-dose study. Clinical Therapeutics, 2008, 30, 1766-1781.	2.5	49
12	Effect of dutasteride, tamsulosin and the combination on patientâ€reported quality of life and treatment satisfaction in men with moderateâ€ŧoâ€severe benign prostatic hyperplasia: 2â€year data from the CombAT trial. BJU International, 2009, 103, 919-926.	2.5	44
13	The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study. Prostate Cancer and Prostatic Diseases, 2009, 12, 369-374.	3.9	40
14	Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH. Prostate Cancer and Prostatic Diseases, 2009, 12, 152-159.	3.9	19
15	Onceâ€daily trospium chloride 60 mg extendedâ€release provides effective, longâ€term relief of overactive bladder syndrome symptoms. Neurourology and Urodynamics, 2011, 30, 1214-1219.	1.5	18
16	Diary and Patient-Reported Outcomes in Patients with Severe Overactive Bladder Switching from Tolterodine Extended Release 4 mg/day to Solifenacin Treatment. Clinical Drug Investigation, 2009, 29, 305-316.	2.2	17
17	Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: Longâ€ŧerm results from the combination of dutasteride and tamsulosin study. International Journal of Urology, 2012, 19, 1031-1035.	1.0	13
18	Efficacy and Safety of Ciprofloxacin Oral Suspension Versus Trimethoprim-Sulfamethoxazole Oral Suspension for Treatment of Older Women with Acute Urinary Tract Infection. Journal of the American Geriatrics Society, 2001, 49, 1606-1613.	2.6	12

#	Article	IF	CITATIONS
19	BCG in management of transitional cell carcinoma invasive to prostate. Urology, 1989, 34, 381-382.	1.0	3
20	Long-Term Efficacy and Tolerability of Abdominal Once-Yearly Histrelin Acetate Subcutaneous Implants in Patients with Advanced Prostate Cancer. Prostate Cancer, 2014, 2014, 1-5.	0.6	3
21	A Retrospective Study Evaluating the Efficacy and Tolerability of Intra-abdominal, Once-yearly Histrelin Acetate Subcutaneous Implants in Patients. UroToday International Journal, 2012, 05, .	0.1	1